BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 15695169)

  • 1. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
    Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
    J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of M-II, the major human metabolite of ramelteon.
    Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K
    Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.
    Imbesi M; Uz T; Manev H
    Neuroscience; 2008 Sep; 155(4):1160-4. PubMed ID: 18664376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
    Fisher SP; Davidson K; Kulla A; Sugden D
    J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells.
    Imbesi M; Uz T; Dzitoyeva S; Manev H
    Neurosci Lett; 2008 Jul; 439(1):34-6. PubMed ID: 18501512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GR196429: a nonindolic agonist at high-affinity melatonin receptors.
    Beresford IJ; Browning C; Starkey SJ; Brown J; Foord SM; Coughlan J; North PC; Dubocovich ML; Hagan RM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1239-45. PubMed ID: 9618428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune hepatitis in association with ramelteon.
    Fourman LT; Robert Meyer B
    J Clin Gastroenterol; 2013 Aug; 47(7):651-4. PubMed ID: 23632362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
    Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
    Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice.
    Miyamoto M
    Neurosci Lett; 2006 Jul; 402(3):201-4. PubMed ID: 16730121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.
    Osanai K; Kobayashi Y; Otsu M; Izawa T; Sakai K; Iwashita M
    Hum Cell; 2017 Jul; 30(3):209-215. PubMed ID: 28382516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin receptor activation suppresses adrenocorticotropin production via BMP-4 action by pituitary AtT20 cells.
    Tsukamoto N; Otsuka F; Ogura-Ochi K; Inagaki K; Nakamura E; Toma K; Terasaka T; Iwasaki Y; Makino H
    Mol Cell Endocrinol; 2013 Aug; 375(1-2):1-9. PubMed ID: 23701823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T; Stubbs C; Walsh JK
    Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia.
    Richardson G; Wang-Weigand S
    Hum Psychopharmacol; 2009 Mar; 24(2):103-11. PubMed ID: 19090503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramelteon: TAK 375.
    Drugs R D; 2005; 6(3):186-8. PubMed ID: 15869323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin receptors mediate improvements of survival in a model of polymicrobial sepsis.
    Fink T; Glas M; Wolf A; Kleber A; Reus E; Wolff M; Kiefer D; Wolf B; Rensing H; Volk T; Mathes AM
    Crit Care Med; 2014 Jan; 42(1):e22-31. PubMed ID: 24145838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New selective ligands of human cloned melatonin MT1 and MT2 receptors.
    Audinot V; Mailliet F; Lahaye-Brasseur C; Bonnaud A; Le Gall A; Amossé C; Dromaint S; Rodriguez M; Nagel N; Galizzi JP; Malpaux B; Guillaumet G; Lesieur D; Lefoulon F; Renard P; Delagrange P; Boutin JA
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):553-61. PubMed ID: 12764576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.